

SECTION: Clinical
ID NO.: CPI-9-208
PAGE: 1 of 20

ISSUE DATE: May 02, 2005

ISSUE.REVISION: 1.33

REVISION DATE: July 24, 2024
APPROVED BY: Hospital Program

Authority

## **Clinical Process Instruction Manual**

## **Donor Assessment – Combined Organ and Tissue Process Instruction**

#### Policy:

The accurate and appropriate assessment of a potential organ and tissue donor is an essential step in the donation process to help minimize risk of disease transmission and other adverse outcomes associated with transplantation. This process is a combined effort of health care professionals, and Trillium Gift of Life Network's (TGLN) Referral Triage Coordinators (RTC), Clinical Services Coordinators (CSC), Tissue Coordinators (TC), Clinical Responders (CR) and/or Specialist - Organ and Tissue Donation (S-OTD) in consultation with TGLN's Chief Medical Officer (CMO) or on-call designate, transplant physicians and/or tissue banks.

For the purposes of this document, TGLN coordinator refers to the S-OTD or TC, but in some instances the CSC, CR or Clinical Specialist (CS) may fill this role.

A combination of a thorough review of the potential donor's medical record and a completed donor Medical and Social History Questionnaire (MSHx) is essential in gathering past medical history and clinical data related to critical illness/trauma (see *Donor Medical and Social History – Organ or Combined Organ & Tissue Process Instruction, CPI-9-207*). This information is collected, stored and made available to transplant programs and tissue banks as appropriate. iTransplant as well as the *Assessment Form: Organ/Combined Organ & Tissue Donor or Assessment Form: Tissue Donor* (see Exhibits 1 and 2) may be used to collect and store relevant data.

Screening and testing is to be facilitated as quickly and efficiently as possible. However, specimen collection and specialized testing to evaluate organ and/or tissue suitability are not performed until consent for donation is documented. The exception to this is that testing may proceed for organ donors if next-of-kin (NOK) give approval to do so in advance of documented consent.

Most 'contraindications' to organ donation are not absolute. In these situations, exceptional distribution (EXD) provisions may apply. See *Exceptional Distribution Process Instruction, CPI-9-217* for a complete list of these conditions. If it is not predetermined, as above, TGLN's CMO or on-call designate will determine whether an offer for an organ falls under EXD circumstances. Organs that are safe for transplantation, are offered by the CSC on behalf of CMO-Transplant. The organs are considered safe for transplantation when they are processed in accordance with Health Canada regulations. Organs that are not considered safe for transplant by Health Canada's Cells, Tissues and Organs (CTO) regulations can be exceptionally distributed if they have exclusionary criteria. A preliminary discussion with relevant transplant programs in order to assess interest in potential organs for transplantation may be necessary.

Tissue donation may also be possible despite the presence of 'adverse conditions'. However, TGLN will not proceed with donation of tissues for transplantation if absolute contraindications are present (see *General Tissue Donation Criteria and Contraindications, CPI-9-262*) or if tissue bank specific criteria are not met.



SECTION: Clinical
ID NO.: CPI-9-208
PAGE: **2** of 20

ISSUE DATE: May 02, 2005

ISSUE.REVISION: 1.33

REVISION DATE: July 24, 2024

APPROVED BY: Hospital Program

Authority

## **Clinical Process Instruction Manual**

## **Donor Assessment – Combined Organ and Tissue Process Instruction**

The decision to accept organs and/or tissues following an offer from TGLN rests with the transplant programs and/or tissue banks receiving the offer. Some Tissue Banks have designated the authority to accept tissue on their behalf to TGLN.

#### **Process:**

When a potential donor has been identified and referred, preliminary medical suitability determination begins. Once preliminary medical suitability for absolute exclusions is confirmed, a more comprehensive donor assessment process is undertaken by a TGLN coordinator. The following procedure is divided into three parts – Part A: Determining Preliminary Medical Suitability, Part B: Organ or Combined Organ and Tissue Donation, and Part C: Tissue-Only Donation.

## **PART A: Determining Preliminary Medical Suitability**

- 1. On receiving a referral of a potential organ donor, the RTC or designate will enter relevant preliminary data into iTransplant and/or complete the *Triage Form*.
- 2. At time of referral, the RTC or CSC will obtain the following information and enter it into iTransplant. If the referral is from an S-OTD hospital or if an S-OTD or CR is on site, the S-OTD or CR may be assigned to obtain this information. Any available updates to this information will be entered into iTransplant each time the S-OTD or RTC follows up on an open referral.
  - 2.1. Admission history including history of cardiac arrest and downtime
  - 2.2. Medical history including cancer history if applicable
  - 2.3. Brainstem reflexes
  - 2.4. Chemistry
  - 2.5. CBC
  - 2.6. ABGs and CXR results
  - 2.7. Vital signs including ventilator settings
  - 2.8. The RTC or S-OTD will make a clinical note documenting the patient's neurological status, plan of care, any relevant family dynamics and any changes since the last follow up.
- 3. The RTC and/or S-OTD determine preliminary medical suitability for donation prior to the donation discussion with the NOK for absolute exclusions only. When death has been determined by neurologic criteria and consent obtained or a pre-mortem consent for the purposes of donation after death determination by circulatory criteria (DCC) is obtained, the donation process begins, and medical suitability of the potential donor is further evaluated.
- 4. The S-OTD or designate will complete the assessment of the donor using the following:
  - chart review with patient identification verification (first and last name, date-of-birth (DOB) and medical record number (MRN));



SECTION: Clinical
ID NO.: CPI-9-208
PAGE: 3 of 20

ISSUE DATE: May 02, 2005

ISSUE.REVISION: 1.33

REVISION DATE: July 24, 2024
APPROVED BY: Hospital Program

Authority

## **Clinical Process Instruction Manual**

## **Donor Assessment – Combined Organ and Tissue Process Instruction**

- If evidence of cancer is noted, obtain the following reports (if available): operative notes, pathology reports, cancer care treatment protocols, follow-up care, follow-up imaging reports
- Review case with TSP to discuss any additional testing/imaging and/or interest calls as needed
- donor medical and social history questionnaire;
- physical examination for trauma and evidence of high-risk behavior, signs of malignancy, infection and/or trauma to the retrieval site.
- 5. If proceeding with donation would contravene relevant standards, the TGLN coordinator will consult *Exceptional Distribution Process Instruction, CPI-9-217* and/or TGLN's CMO or on-call designate to determine whether or not an EXD circumstance is present prior to offering organs. The coordinator will advise the CMO or on-call designate regarding any extenuating circumstances such as high status or seropositive potential organ recipients, as applicable.
- 6. If the coordinator or CMO or on-call designate determines that organs should be offered with respect to EXD provisions, the coordinator will contact the relevant transplant programs to determine if they will accept such offers, documenting as appropriate in accordance with the *Exceptional Distribution Process Instruction, CPI-9-217.*
- 7. In some cases, it may be necessary for the coordinator to conduct a preliminary conversation with transplant programs for interest in organ(s) for transplantation. For instance, to address resource issues such as donor work-up and/or recovery, requests for delay or acceleration of process, discussion and verification of medical status, etc. The coordinator will advise the transplant program that the call is intended to assess preliminary interest in organ(s) for transplantation, and is not to be construed as an organ offer or allocation.
  - 7.1. In addition to the information collected at time of referral and on daily updates (see 2.1 through 2.8), the following information will be required for an interest call:
    - Height
    - Weight
    - ABO (if available)
    - Abdominal imaging (if available)
    - CXR image
    - Positive cultures and treatment if applicable
    - Medications
  - 7.2. For patients with a history of cancer a, TSP call should only be completed after completing a review of hospital and family doctor records for the following details:
    - 7.2.1. Cancer diagnosis and date



SECTION: Clinical
ID NO.: CPI-9-208
PAGE: 4 of 20

ISSUE DATE: May 02, 2005

ISSUE.REVISION: 1.33

REVISION DATE: July 24, 2024
APPROVED BY: Hospital Program

Authority

## **Clinical Process Instruction Manual**

## **Donor Assessment – Combined Organ and Tissue Process Instruction**

- 7.2.2. Treatment details and dates
- 7.2.3. Follow-up details
- 7.2.4. Surgical and pathology notes if applicable
- 7.2.5. Any other available info about the cancer history

Contraindications to donation are outlined in *Exceptional Distribution Process Instruction, CPI-9-217.* 

All organs, that are safe for transplantation, are offered by the CSC on behalf of CMO-Transplant. The organs are considered safe for transplantation when they are processed in accordance with Health Canada regulations. Organs not deemed suitable for transplant can be EXD if they have exclusionary criteria.

- 8. After interest has been confirmed for composite tissue with the transplant program, the coordinator will approach family for consent for composite tissue if the discussion did not occur during the primary donation discussion.
- 9. For contraindications specific to particular tissue banks, see *Tissue Bank Profiles* on the Online Resource Centre (ORC).

#### **PART B: Organ or Combined Organ and Tissue Donation**

The TGLN coordinator will gather all relevant donor information including the following:

Note: Where a coordinator is present on-site, information shall be communicated to the Provincial Resource Centre (PRC) coordinator in a timely manner.

#### 10. Referral:

The coordinator will record the name and contact number for the referring individual.

#### 11. Non-Ontario Offer:

Preliminary information pertaining to organ offers from other programs, and information related to any primary/backup offers, i.e.: Operating Room (OR) time, organs being recovered, whether there is an EXD, and the reason why is also recorded. See *Non-Ontario Organ Donation*, *CPI-9-101*.

#### 12. Donor Information:

The coordinator will validate the donor's identification and verify it with the assigned TGLN donor number. See *Donation Support Process Instruction, CPI-9-103*. Donor information collected and documented includes:

First and last name



SECTION: Clinical
ID NO.: CPI-9-208
PAGE: **5** of 20

ISSUE DATE: May 02, 2005

ISSUE.REVISION: 1.33

REVISION DATE: July 24, 2024
APPROVED BY: Hospital Program

Authority

## **Clinical Process Instruction Manual**

## **Donor Assessment – Combined Organ and Tissue Process Instruction**

- DOB
- MRN
- the cause-of-death or diagnosis (as applicable),
- · admission height,
- · admission weight,
- age,
- ABO type and subtype if donor is A or AB (if subtyping is available),
- total lung capacity (TLC),
- date and time of death,
- coroner's case and if so, was the coroner's permission obtained

If an autopsy is planned, the location of the planned autopsy and the planned disposition of any unused organs or tissues are also documented. Refer to *Coroner's Case Process Instruction*, *CPI-9-203* to determine how results are obtained and reported.

#### 13. Admission History:

The coordinator will obtain required information from the potential donor's hospital medical record including Emergency Medical Service (EMS) forms, physician's notes, and Emergency Department (ED) and Intensive Care Unit (ICU) flow sheets. Include admission details, intubation date and time, whether the intubation was traumatic, any arrests and/or cardiopulmonary resuscitation (CPR)/defibrillation, resuscitation drugs, duration of the arrest, trauma and/or surgery during this admission.

#### 14. Drug Screen:

Unless the possibility of an overdose is ruled out by the physician, drug screening (blood and urine) should be considered for potential donors hospitalized less than 48 hours, and those with questionable medical/social histories or unknown cause-of-death. The S-OTD and/or CSC notes any sedatives/medications previously administered which may test positive in any drug screen. If the donor hospital cannot perform an adequate drug screen, Hospital for Sick Children (HSC) toxicology department may be utilized. See Exhibit 3 for the *HSC Toxicology Form*.

**Note:** If the donor is being transferred to another hospital for recovery, the S-OTD, in collaboration with the CSC, will consider the receiving hospital's protocols regarding drug screening prior to death determination by neurologic criteria (DNC).

#### 15. Previous Positive Cultures:



SECTION: Clinical
ID NO.: CPI-9-208
PAGE: **6** of 20

ISSUE DATE: May 02, 2005

ISSUE.REVISION: 1.33

REVISION DATE: July 24, 2024
APPROVED BY: Hospital Program

Authority

## **Clinical Process Instruction Manual**

## **Donor Assessment – Combined Organ and Tissue Process Instruction**

Any positive cultures obtained during this admission and prior to consent should be documented, including the source (blood, urine, sputum, etc.), the results, and any treatment provided.

#### 16. Medications:

The S-OTD or designate documents medications administered from the time of consent to organ recovery. (The medications administered prior to hospitalization (home meds including supplements will be captured in the donor's medical social history questionnaire or the patient's medical record).

Medications administered in the hospital to be documented include the following:

- Hemodynamic agents (i.e. vasopressors, inotropes)/Cardiovascular agents (i.e. antihypertensives)
- Antibiotics, Antifungals and Antivirals
- Immune Modulating Agents (i.e. immunosuppressants and steroids)
- Blood glucose regulators
- Anticoagulants
- Hormonal agents (i.e. DDAVP)
- Analgesia and Sedation PRN included

Include the date and time infusions were initiated. Changes to infusion rates, including the times, are documented and may be updated verbally by the on-site coordinator. Dosages are calculated in mcg/kg/min or unit/min or mcg/min, i.e.: dosage per unit of time (not dosage per volume of fluid administered), i.e.: Levophed 0.5 mcg/kg/min (not Levophed 4 mg/250 mL).

#### 17. Serology:

The coordinator ensures all tests in TGLN's required infectious diseases screening panel are completed. See *Infectious Disease Testing – STAT Process Instruction, CPI-9-211*. The CSC ensures that the results of serology testing are documented. A copy is included in the TGLN donor chart. The coordinator ensures the lab is aware of the testing and confirms the estimated time to completion with the lab. Any pending serology tests are noted by the coordinator and may be considered as an EXD if the results will not be available prior to transplant.

#### 17.1 Pediatric Serology Testing:

For pediatric donors, maternal serology testing is also required if the donor is 18 months old or less, or on any child who was breastfed within the last 12 months. See *Maternal Serology* – *SickKids Process Instruction, CPI-9-266.* However, the following exceptions apply:

- 17.1.1 For donors ≤ 28 days old who have no obvious potential exposure to a blood-borne pathogen after birth, only the birth mother's STAT serology testing is required.
- 17.1.2 For donors ≥ 29 days old, where NAT testing has already been completed on the infant donor, birth mother STAT serology testing is not required.



SECTION: Clinical
ID NO.: CPI-9-208
PAGE: **7** of 20

ISSUE DATE: May 02, 2005

ISSUE.REVISION: 1.33

REVISION DATE: July 24, 2024

APPROVED BY: Hospital Program

Authority

## **Clinical Process Instruction Manual**

## **Donor Assessment – Combined Organ and Tissue Process Instruction**

#### 18. Past Medical & Social History Questionnaire:

The S-OTD or designate will obtain required information from the potential donor's hospital medical record, family physician and NOK using the donor medical and social history questionnaire to guide data collection.

**Important:** positive or unknown findings are shared with transplant programs and tissue banks. If the donor is 18 months old or less, and/or has been breast-fed in the past 12 months, a maternal donor medical and social history questionnaire must also be obtained and a maternal blood sample sent for appropriate STAT serology. If for any reason either one of these cannot be obtained, the organs would be considered under EXD provisions.

#### 19. Hemodilution Calculation:

The S-OTD or designate will perform a hemodilution calculation prior to drawing blood specimens for serology testing, to determine whether pre-dilution (stored) blood specimens should be obtained for testing. A calculation must be performed on every blood sample drawn for testing including non-stat testing. Blood product administration is documented by the S-OTD for the previous 48 hours in the donor management system. See *Hemodilution Calculation Process Instruction, CPI-9-210*. If an organ is offered from an out-of-province program, the hemodilution calculation is done by the offering program, and details of the calculation are given to the CSC.

#### 20. Physical Assessment:

The S-OTD or designate will conduct a thorough head-to-toe front-and-back assessment of the potential donor for any evidence of high-risk behavior, signs of malignancy, bacterial or viral infection, and trauma to the recovery site. Findings shall be documented, including line placement and the presence of tattoos, presence of piercings, scars (surgical or trauma), fractures, abrasions/lesions and/or rashes, signs of malignancies and infections. If there is consent for composite tissue, a detailed assessment of the site is completed on the *Limb Physical Assessment Form.* See Exhibit 5.

The physical assessment shall be performed within 30 days of the scheduled date of the medical assistance in dying procedure or withdrawal of life-sustaining measures (WLSM).

#### 21. Hemodynamics:

The S-OTD notes any significant hypertensive or significant hypotensive episodes occurring since after consent for organ donation has been obtained, and documents the start time, duration, treatment and/or medications administered during this period. For most adults, normal blood pressure (BP) at rest is within the range of 100 - 130 millimeters mercury (mmHg) systolic and 60 - 80 mmHg diastolic. The following guidelines can be used for evaluating significant hypertensive and hypotensive episodes: hypertension can be defined as any systolic blood pressure above 180 sustained for more than 10 minutes and any diastolic blood pressure sustained above 110 for more than 10 minutes and significant hypotension can be defined as any sustained MAP below 60 for more than 20 minutes. Any episodes meeting this guideline need to be charted. Subsequent vital signs including central venous pressure (CVP)/right atrial pressure (RA), pulmonary artery pressure



SECTION: Clinical
ID NO.: CPI-9-208
PAGE: **8** of 20

ISSUE DATE: May 02, 2005

ISSUE.REVISION: 1.33

REVISION DATE: July 24, 2024
APPROVED BY: Hospital Program

Authority

## **Clinical Process Instruction Manual**

## **Donor Assessment – Combined Organ and Tissue Process Instruction**

(PAP), pulmonary capillary wedge pressure (PCWP), and cardiac index (CI) if available, urinary output (U/O) and intravenous (IV) intake are communicated to the (PRC) and documented every 6 hours and as needed.

## 22. General minimum testing information gathered for all donors will include:

- admission height
- admission weight
- ABO blood type and subtype if donor is A or AB (if subtyping is available)
- complete blood count (CBC) to include at minimum hemoglobin, hematocrit, white blood cell (WBC), platelet counts
- serum electrolytes, to include at minimum sodium and potassium
- serum creatinine
- chest x-ray (CXR) or chest CT (within a minimum of 30 days before organ retrieval)

**Important:** To confirm height and weight measurements, the donor shall be weighed using a bed scale and their height shall be measured using a measuring tape at the time of the physical assessment. If a bed scale is unavailable, then the weight will be specified as estimate.

#### 23. Laboratory Data:

The S-OTD or designate records trends of all blood work and communicates them to the CSC on an ongoing basis. If the patient was transferred, include blood work results from the referring centre if available. The CSC will record ongoing updates every 6 hours (q6h). For all donor information which is transcribed from hospital charts, the S-OTD verifies the transcription before entering the data into the donor chart. Transcribed data should only be truncated if fields cannot fit the data in its entirety. See *Organ Specific Data Collection Process Instruction, CPI-9-215*.

#### 24. Routine Cultures:

The S-OTD or designate will ensure that a full set of cultures (blood, urine, and sputum) have been sent. For follow-up reporting, see *Microbiology Testing Process Instruction, CPI-9-214*.

#### 25. Heart Profile:

The S-OTD or designate will obtain a CXR, electrocardiogram and echocardiogram (if required). The S-OTD or designate ensures that a left ventricular (LV) ejection fraction/grade is included in the echocardiogram report. An angiogram will also be arranged if requested. In situations where an angiogram cannot be completed when requested, a CT coronary angiogram may be an acceptable alternative test. The S-OTD or designate will discuss transplant program acceptance of a CT coronary angiogram in place of an angiogram with the CSC prior to making arrangements for the test. Written reports are acceptable for allocation purposes; however, imaging recordings (discs or tapes) are encouraged if available.



SECTION: Clinical
ID NO.: CPI-9-208
PAGE: **9** of 20

ISSUE DATE: May 02, 2005

ISSUE.REVISION: 1.33

REVISION DATE: July 24, 2024

APPROVED BY: Hospital Program

Authority

## **Clinical Process Instruction Manual**

## **Donor Assessment – Combined Organ and Tissue Process Instruction**

#### 26. Lung Profile:

The on-site coordinator will document findings of current CXR, an admission CXR, or earlier report. Record the appearance and amount of secretions being suctioned, as well as the stat gram stain results from any sputum samples sent. A bronchoscopy is required if the patient's condition permits and a BAL for gram stain is collected. A sputum specimen shall be tested within 30 days before donation, or endotracheal aspirate, bronchial wash, or bronchoalveolar lavage (BAL) specimen for culture at the time of organ retrieval. Chest circumference is measured at the request of transplant programs. TLC is calculated. The S-OTD or designate will request that CXRs be repeated q12h (if possible) and hard copies retained for reading by the lung transplant team when they arrive for the surgical recovery, or made available to them electronically. Oxygen challenge testing is not typically completed for patients who donate after medical assistance in dying. For additional lung requirements, see *Organ Specific Data Collection Process Instruction, CPI-9-215*.

## 27. Blood Gases and Ventilator Settings:

Current challenge arterial blood gases (ABGs) on 100% FiO<sub>2</sub> and PEEP 8 – 10 cm H<sub>2</sub>O, 10 minutes after recruitment maneuvers (30 PEEP x 30 seconds) are completed q6h or as needed (prn). If recruitment maneuvers are not performed prior to ABGs or if patient is on a PEEP higher than 8 - 10, this information will be communicated to the CSC. Ventilator settings (including peak airway pressures) are documented q2-4h by the S-OTD and CSC, as applicable, and each time a ventilator change is made. For all donor information which is transcribed from hospital charts, the OTDC verifies the transcription before entering the data into the donor chart.

#### 28. Abdominal Profile:

The testing (abdominal CT and/or ultrasound), measurements and medication that make up the abdominal profile are dependent on which organs are being considered for donation. See *Organ Specific Data Collection Process Instruction, CPI-9-215* for organ specific requirements. All relevant information is collected and remains part of the permanent donor record.

#### 29. Kidney/Pancreas Profile:

The CSC will confirm that a creatinine clearance and glomerular filtration rate (GFR) has been auto-calculated in the donor chart if there is consent for kidney, kidney-pancreas, or isolated pancreas. For pediatric donors (< 18 years of age), the eGFR calculation that is auto-calculated by iTransplant should not be used. CSCs must communicate the serum creatinine to the kidney transplant program at the time of offer. Renal imaging (full report, including kidney size, cortical thickness and evidence of obstruction) will be done on all potential kidney donors. requirement, See *Organ Specific Data Collection Process Instruction, CPI-9-215* for organ specific requirements. For all donor information which is transcribed from hospital charts, the OTDC verifies the transcription before entering the data into the donor chart.

#### 30. Urinalysis:



SECTION: Clinical ID NO.: CPI-9-208 PAGE: **10** of 20

ISSUE DATE: May 02, 2005

ISSUE REVISION: 1.33

REVISION DATE: July 24, 2024
APPROVED BY: Hospital Program

Authority

## **Clinical Process Instruction Manual**

## **Donor Assessment – Combined Organ and Tissue Process Instruction**

The on-site coordinator will request if there is consent for kidneys, kidney-pancreas, or isolated pancreas, that a complete urinalysis is documented. A urine dipstick result is satisfactory if urine random and microscopic (R&M) testing is unavailable. For all donor information which is transcribed from hospital charts, the OTDC verifies the transcription before entering the data into the donor chart.

#### 31. Composite Tissue Profile:

The coordinator will collect the height of parents if the donor and recipient are < 16 years of age and will complete a Fitzpatrick scale assessment. Additional test results to be recorded include capillary refill, Allen's test, Doppler ultrasound and an x-ray of the limb. Invasive lines will be repositioned to alternate limb, if needed. The patient identification band is also moved to an alternative limb.

#### 32. Clinical Notes:

Used by all coordinators to document all conversations with the referring centre, family, coroner, CMO or on-call designate, transplant physicians, etc. and any activities relevant to the donation.

33. Using the *TGLN Donor Case Closure Checklist*, the CSC makes sure all pertinent data has been collected. See Exhibit 4.

#### **Part C: Tissue-Only Donation**

The sections numbered below refer to data collection specific for tissue exclusive donation. Certain cases will require on-site coordinator support as assessed by the TC, CSC and S-OTD when a plan of care is developed or as per the Tissue Profile.

#### 34. Referral:

Once the initial referral/referral worksheet is complete, the coordinator proceeds to complete the assessment section of the chart.

#### 35. Donor Suitability

Suitability criteria will be established by the Medical Director-Tissue and will be in accordance with Health Canada/Canadian Standards Association (HC/CSA) and American Association of Tissue Banks (AATB) standards. Potential donors will be evaluated on an individual basis by chart review and physical assessment, noting the size of the donor, current medical status, and skin condition.

## 36. Review of Medical History

A preliminary review of the donor's medical history must be conducted by TGLN personnel before recovery coordination can proceed. The TC or S-OTD will obtain required admission information from the potential donor's hospital medical record (EMS forms, physician's notes, ER and ICU flow sheets), including medications, white blood cell counts (WBCs), temperatures, cultures, and CXRs.



SECTION: Clinical
ID NO.: CPI-9-208
PAGE: 11 of 20

ISSUE DATE: May 02, 2005

ISSUE.REVISION: 1.33

REVISION DATE: July 24, 2024
APPROVED BY: Hospital Program

Authority

## **Clinical Process Instruction Manual**

## **Donor Assessment – Combined Organ and Tissue Process Instruction**

The TC or S-OTD will document if any intravenous (IV) fluids were given within the previous hour or if any blood products were given within the previous 48 hours. Additional information may be required from the attending and/or family physician, coroners, etc.

### 37. Disease Screening

TGLN will obtain the following information from the NOK or physician as to whether any of the following applies, in which case the tissue will not be recovered:

- evidence of significant active infection, specifically to communicable diseases. These include, but are not limited to: septicemia, viral disease (e.g., HIV, viral hepatitis, West Nile virus, rabies, etc.), human transmissible spongiform encephalopathies, untreated syphilis, clinically active tuberculosis, leprosy, or systemic mycosis;
- risk factors for any communicable diseases
- history of any other exclusionary diseases or conditions as outlined in the *General Tissue Donation Criteria and Contraindications Process Instruction, CPI-9-262.*

#### 38. Coroner Involvement:

Determine if the case requires the involvement of a coroner. If so, identify the name and phone number of the coroner and whether an autopsy is pending. Identify if there are any coroner's restrictions to the donation.

#### 39. Outside Contacts:

The donor's address and authorizing persons' information is documented. Additionally, family notification, body refrigeration and initial medical suitability to proceed are all documented.

## 40. Hemodilution Calculation:

To determine whether pre-dilution (stored) blood specimens should be obtained for testing, the onsite TGLN coordinator or the TC/TRC (as applicable) will calculate the hemodilution factor prior to drawing blood specimens for serology testing. See *Hemodilution Calculation Process Instruction, CPI-9-210.* The TC/TRC will also document if the patient was transferred from another site; this includes date and time, if patient arrived via ambulance (including arrival date and time), plus any fluids administered at admission time. If information is collected by phone, the name of the healthcare professional providing the information relevant for the calculation will be recorded.

#### 41. Donor Risk

The NOK or designate will complete the relevant *Donor Risk Assessment Interview(s)* with the TC or S-OTD. Questions will be formed using *Health Canada's Safety of Human Cells, Tissues and Organs for Transplantation* (CTO) *Regulations* and AATB standards. Questions should be asked in order to evaluate whether a contraindication exists.



SECTION: Clinical
ID NO.: CPI-9-208
PAGE: 12 of 20

ISSUE DATE: May 02, 2005

ISSUE REVISION: 1.33

REVISION DATE: July 24, 2024
APPROVED BY: Hospital Program

Authority

## **Clinical Process Instruction Manual**

## **Donor Assessment – Combined Organ and Tissue Process Instruction**

The TC or S-OTD will document the donor's name and the relationship of the donor to the interviewee. Separate questionnaires must be completed for each interview conducted. See *Medical & Social History – Tissue Process Instruction, CPI-9-261*.

#### 42. Clinical Notes:

All coordinators are to document all conversations with referring centre, coroner, CMO or on-call designate, relevant tissue banks and any activities relevant to the donation.

43. On acceptance of tissue(s) for transplant by tissue banks (as applicable), all relevant data is forwarded or faxed to the relevant tissue banks and recovery personnel by the TC/CSC or designate, as appropriate.

#### Records:

Record Name	Form No. (if applicable)	Record Holder	Record Location	Record Retention Time (as a minimum)
Assessment Form: Organ/Combined Organ & Tissue Donor	CSF-9-15	PRC	PRC	16 years
Assessment Form Tissue Donor	CSF-9-16	PRC	PRC	16 years
Limb Physical Assessment	CSF-9-18	PRC	PRC	16 years
Donor Medical & Social History Questionnaire	CSF-9-14	PRC	PRC	16 years
Triage Form	CSF-9-1	PRC	PRC	16 years
Eye-Only Donor Risk Assessment Interview (Donor > 10 years old)	CSF-9-214	PRC	PRC	16 years



SECTION: Clinical
ID NO.: CPI-9-208
PAGE: 13 of 20

ISSUE DATE: May 02, 2005

ISSUE REVISION: 1.33

REVISION DATE: July 24, 2024

APPROVED BY: Hospital Program

Authority

## **Clinical Process Instruction Manual**

## **Donor Assessment – Combined Organ and Tissue Process Instruction**

Eye-Only Donor Risk Assessment Interview (Child Donor ≤ 10 years old)	CSF-9-215	PRC	PRC	16 years
Eye-Only Donor Risk Assessment Interview Birth Mother	CSF-9-216	PRC	PRC	16 years
Donor Risk Assessment Interview (Donor > 10 years old)	CSF-9-261	PRC	PRC	16 years
Donor Risk Assessment Interview (Child Donor ≤ 10 years old)	CSF-9-262	PRC	PRC	16 years
Donor Risk Assessment Interview Birth Mother	CSF-9-263	PRC	PRC	16 years

#### References:

- Ontario Organ or Combined Organ and Tissue Donation Process Instruction, CPI-9-100
- Non-Ontario Organ Donation Process Instruction, CPI-9-101
- Donation Support Process Instruction, CPI-9-103
- Ontario Tissue Exclusive Referral Donation Process Instruction, CPI-9-160
- Coroner's Case Process Instruction, CPI-9-203
- Hemodilution Calculation Process Instruction, CPI-9-210
- Infectious Disease Testing STAT Process Instruction, CPI-9-211
- Microbiology Testing Process Instruction, CPI-9-214
- Organ and Composite Tissue Specific Data Collection Process Instruction, CPI-9-215
- Exceptional Distribution Process Instruction, CPI-9-217
- Medical & Social History Tissue Process Instruction, CPI-9-261
- General Tissue Donation Criteria and Contraindications, CPI-9-262



SECTION: Clinical
ID NO.: CPI-9-208
PAGE: **14** of 20

ISSUE DATE: May 02, 2005

ISSUE.REVISION: 1.33

REVISION DATE: July 24, 2024
APPROVED BY: Hospital Program

Authority

## **Clinical Process Instruction Manual**

## **Donor Assessment – Combined Organ and Tissue Process Instruction**

- Maternal Serology SickKids, CPI-9-266
- Health Canada: Safety of Human Cells, Tissues and Organs for Transplantation Regulations, Canada Gazette, Part II, Vol. 141, No. 13, June 27, 2007
- CAN/CSA-Z900.1: Cells, Tissues, and Organs for Transplantation and Assisted Reproduction: General Requirements, Canadian Standards Association
- CAN/CSA-Z900.2.3: Perfusable organs for transplantation, Canadian Standards Association
- Standards for Tissue Banking, American Association of Tissue Banks, United StatesD4.100, D4.220, D4.230, D4.300.



SECTION: Clinical
ID NO.: CPI-9-208
PAGE: **15** of 20

ISSUE DATE: May 02, 2005

ISSUE.REVISION: 1.33

REVISION DATE: July 24, 2024
APPROVED BY: Hospital Program

Authority

# **Clinical Process Instruction Manual**

# **Donor Assessment – Combined Organ and Tissue Process Instruction**

# Exhibit 1: Assessment Form: Organ/Combined Organ & Tissue Donor Page 1

LN DONO	R#				**Health Canad	da Requirement Data Fo	CSF-6 mat: dd/mmmyyyy
	Trillium Gift of Life Network		ife.on.ca	nto, Ontario M5G	12CS		
		SESSMENT FO	RM: ORGAN/C	OMBINED O	RGAN & T	ISSUE DONOR	
REFER							
DATE:	/UNIT:		PHONE #:			FAX #:	VE.
MRN#		OHIP#:				OTDC/STAFF:	VE.
						OIDGGIAT.	CONSENT YELD I
	S RESTRICTIONS					YO NO LOCATION:	CONSCIENT. 1 LI IN L
		JNUSED ORGANS OR TIS	SUES (CORONEIPS CASE)		O O TENDERO	TO NO ECONOMIC	
CSC O			ONTARIO OFFER:		USA 🗆	ADMIN CTO #	:
OFFICIALIS-1	OFFEDER.		DOMOR COO.			8AF:\$ W	AIVER3: YO NO
		ECLINED: YO NO RE				IGMP.8	AIVERS: TO NO
OTHER OF		ECCINED. TO NO NO	Sydicin(s).		OR TIME:	HLA: YO N	□ SEE REPORT □
	OR INFORMA	TION					
	ore men oreman		AGE:	CSC ONLY			
MALE / EE	MALE DAGE:	DO		AB0:		CBC INITIAL 8:	- (
NDD III	DCD III DATE	OF DEATH:	TIME:	EXCEPTIONAL DIS			
	DEATH / DIAGNO			REASON(s):			
			(Darr. 100			<sup>[1]</sup> CROSS CLAMP DATE:	TIME
** A DMI	SSION HISTO		WIN3	1EC Br	WI NIA LI	CROSS CLAWF DATE.	TIME.
	331014111311						
DATE:			ATION DATE:		TIME:		
ADMISSIO	N DETAILS:			_			
			$\rightarrow$				
		-					
ARRESTS:	YO NO X_	DATE:	TIME: DO	WNTIME:	CPR/DEFIB/CA	RDIOVERSION MEDS:	
TRAUMA./	SURGERY: Y III N	-		TRAN	8FUSIONS: Y 🗖	N D	
CHEST TU	BES: YO NO F	YES: R / L / BILATERA	DATE INSERTED:			DRAINAGE:	
DRUG:	SCREEN DO	NE YES□ NO□	SEE REPORT				
		TIME:	BLOOD/URINE	DATE:		TIME: BLOC	D/URINE
RESULTS:				RESULTS:			
**PREV	IOUS POSIT	VE CULTURES	YES D NO D SE	E REPORT		(I)DOCUMENTED S	EPSIS: YES
DATI				GROWTH		TREA	
		THIS TOS:	TIANUE THE THE				
llees:							
		TING TOOL					
<sup>1]</sup> For con	nbined organ-tis	Bue cases, CSC - NOT CSC Initials	IFY TO OF TISSUE PO			COMPLETED Date:	Time:



SECTION: Clinical ID NO.: CPI-9-208 PAGE: **16** of 20

ISSUE DATE: May 02, 2005

ISSUE\_REVISION: 1.33

REVISION DATE: July 24, 2024


APPROVED BY: Hospital Program

Authority

## **Clinical Process Instruction Manual**

## **Donor Assessment – Combined Organ and Tissue Process Instruction**

# Exhibit 2: Assessment Form: Tissue Donor Page 1



June 8. 2017



SECTION: Clinical
ID NO.: CPI-9-208
PAGE: **17** of 20

ISSUE DATE: May 02, 2005

ISSUE.REVISION: 1.33

REVISION DATE: July 24, 2024


APPROVED BY: Hospital Program

Authority

## **Clinical Process Instruction Manual**

## **Donor Assessment – Combined Organ and Tissue Process Instruction**

## **Exhibit 3: Sample HSC Toxicology Form**





SECTION: Clinical ID NO.: CPI-9-208

PAGE: **18** of 20 ISSUE DATE: May 02, 2005

ISSUE.REVISION: 1.33

REVISION DATE: July 24, 2024
APPROVED BY: Hospital Program

Authority

# **Clinical Process Instruction Manual**

# **Donor Assessment – Combined Organ and Tissue Process Instruction**

**Exhibit 4: Sample TGLN Donor Case Closure Checklist** 

	um of Life		GLN D				C	TD#				
	vork CA	SE CL	.osur	E CHE	:CF	LIST	Hos	spital:				
							Retrieval	Date:				
Hardcopy			Initials	MENTAT		ansplant		Initials			COMMENTS / N	IOTES:
	d (if A, ABO sub-typing a	so unloaded)	initials				(1 CSC & 1 OTDC)	initials	_			
	(Ontario Only - NDD & DCD		_				tole Date & Time					
Consent & Do					•	Uploaded						
Consent for T	reatment (DCD Only)				•	Uploaded						
<ul> <li>WLST Note</li> </ul>						Uploaded						
	ial Questionnaire (and Mate	rnal if applicable)	_		•				_			
Stat Serology     HTLV	(OOP Donors)		+			E-Signatures x						
	OOP Donors): May 1st -	October 31st	+			E-Signatures x						
EBV	COT DOIOTS). May 1st 1	october oraș	+			E-Signatures x						
• Toxo (	Heart Donors)					E-Signatures x						
	al Serology / EBV / Toxo				-	E-Signatures x						
Exceptional C			_		•	Tea of No cine	red, if Yes - Reason					
	ixed to Tx Program		+			Upload fax con						
	faxed to Tx Program form returned to TGLN		+			Upload fax con Uploaded	mination	_	$\dashv$			
	Documents (OPP, AC)				-	Uploaded						
	RNGE Flight(s) Form					Uploaded & e-r	nailed					
<ul> <li>Previous Pos</li> </ul>	tive Cultures and Prelimin		Day 3	Post-OR								
Obtained & R	eported to All Programs 8	Tissue Banks			1	Fator 8 and 11	f	-	-			
Blood     Urine			+		_	Enter & upload Enter & upload			$\dashv$			
Sputun	ı/BAL		+		1.		fax confirmation		$\dashv$			
Other					•	Enter & upload						
	Obtained & Reported		Day 5	Post-OR								
to All Program	ns & Tissue Banks				+	Enter & upload	for confirmation					
Blood     Urine					-	Enter & upload Enter & upload						
Sputuri	I/BAL				-	Enter & upload						
Other					•	Enter & upload	fax confirmation					
						AL COMPUTE					,	
Fransplant Centre			Liver	Rt. Kid	Iney	Lt. Kidney	Pancreas / Islets	Lung	He	art	Small Bowel	VCA
Organ Offered		-		-		_	+		+-			
Organ Decline Reas	on								+-			
Cold Times Obtaine	d								$\top$			
Recipients Off Syste	em											
	0.11			HS	P Kid	iney - CTR W	eb Services					
Make Offer (Ontario	ario Recipients Only)					_						
	ario Recipients Only)											
		ITRA					OR POST / ORG					
ntent at OR			Liver	Rt. Kid	Iney	Lt. Kidney	Pancreas / Islets	Lung	He	art	Small Bowel	VCA
ntent at OR  Outcome & Disposit	ion	-+		+		_	+	_	+-			
Fransplant Centre		-		+					+			
Recip TGLN # in Fir	st Name	-+							$\top$			
	C					ANSPLANT &	TOTAL)			C	SC FINAL CHA	RT SIGN OFF
Entered	Times .	_	itials		ered	) / DCD / ECD Cr		Initials		4 ~		
Enter & Exit 0     Skin Cut & X-		_		_		an Outcome & De		_			Completed ca	
Skin Cut & X      Push to				_	_	ue Outcome & De					Data Entry	y Personnel
	Recovered (TOTAL	.)				ily Services Follo		-		DATE		
DCD Flowshe	et Times (iTrans	olant)			Othe	-						
			CI	IART CHE	CKS					4		
Date	Signature	Date		Sign	ature	Da	te	Signatu	re	SIGN	ATURE:	
Jate	Signature	Date		Sign	ature	Da	te	Signatu	e			



SECTION: Clinical
ID NO.: CPI-9-208
PAGE: 19 of 20

ISSUE DATE: May 02, 2005

ISSUE\_REVISION: 1.33

REVISION DATE: July 24, 2024


APPROVED BY: Hospital Program

Authority

## **Clinical Process Instruction Manual**

## **Donor Assessment – Combined Organ and Tissue Process Instruction**

## **Exhibit 5: Limb Physical Assessment**





SECTION: Clinical
ID NO.: CPI-9-208
PAGE: **20** of 20

ISSUE DATE: May 02, 2005

ISSUE REVISION: 1.33

REVISION DATE: July 24, 2024
APPROVED BY: Hospital Program

Authority

# **Clinical Process Instruction Manual**

# **Donor Assessment – Combined Organ and Tissue Process Instruction**

# Exhibit 6 - Modified Allen's Test with Doppler - Worksheet

Ontario meanti	d Allen's Test With Upper Limb Assessme		. 2 240
TGLN <u>#:</u>			
Date: Time	e:		
Instructions for physician completing assessmen with pressure at the wrist, and determine if there <u>ulnar</u> artery). Then, occlude the <u>ulnar</u> artery with Doppler signal in the palm (flow coming in via the	is a Doppler signal in the p pressure at the wrist, and o	alm (flow coming in via the determine if there is a	
LEFT WRIST	YES	NO	
Left ulnar Doppler signal present			
Left radial Doppler signal present			
RIGHT WRIST	YES	NO	
Right ulnar Doppler signal present		П	
Right <b>radial</b> Doppler signal present Comments:	В	u	
Physician who performed the assessme	ent:		
Signature:	Hospital:		